Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects
Journal of Medicinal Chemistry · 26.09.2024 · 67 (18) · 15968-15995
DOI: 10.1021/acs.jmedchem.4c00966 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 11.09.2024. Verfasst von Xinqi Liang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Laboratory of Neuro-system and Multimorbidity and Targeted Tracer Research and Development Laboratory and Institute of Respi…. Hauptthemen laut MEDLINE: Antineoplastic Agents, HSP90 Heat-Shock Proteins, Neoplasms. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 153 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
Heat shock protein 90 (HSP90), a highly conserved member of the heat shock protein family, regulates various proteins and signaling pathways involved in cancer, making it a promising target for cancer therapy. Traditional HSP90 inhibitors have demonstrated significant antitumor potential in preclinical trials, with over 20 compounds advancing to clinical trials and showing promising results. However, the limited clinical efficacy and shared toxicity of these inhibitors restrict their further clinical use. Encouragingly, developing novel inhibitors using conventional medicinal chemistry approaches─such as selective inhibitors, dual inhibitors, protein-protein interaction inhibitors, and proteolysis-targeting chimeras─is expected to address these challenges. Notably, the selective inhibitor TAS-116 has already been successfully marketed. In this Perspective, we summarize the structure, biological functions, and roles of HSP90 in cancer, analyze the clinical status of HSP90 inhibitors, and highlight the latest advancements in novel strategies, offering insights into their future development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Laboratory of Neuro-system and Multimorbidity and Targeted Tracer Research and Development Laboratory and Institute of Respiratory Health and Frontiers Science Center for Disease-related Molecul…
- Breast Center, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan, China.
- Frontiers Medical Center, Tianfu Jincheng Laboratory, Chengdu, 610212 Sichuan, China.
ORCID-Profile: Yuxi Wang, Jifa Zhang
Förderung
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Liang, X., Chen, R., Wang, C., Wang, Y., & Zhang, J. (2024). Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects. Journal of Medicinal Chemistry, 67(18), 15968-15995. https://doi.org/10.1021/acs.jmedchem.4c00966
Vancouver
Liang X, Chen R, Wang C, Wang Y, Zhang J. Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects. Journal of Medicinal Chemistry. 2024;67(18):15968-15995. doi:10.1021/acs.jmedchem.4c00966
BibTeX
@article{Liang2024,
author = {Liang, Xinqi and Chen, Ruixian and Wang, Chengdi and Wang, Yuxi and Zhang, Jifa},
title = {Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {18},
pages = {15968--15995},
doi = {10.1021/acs.jmedchem.4c00966}
}
EUVIMED